Ketamine Therapy vs. Antidepressants: Which Is More Effective Long-Term?
Depression affects more than 280 million people globally, and finding the right treatment is often a long, frustrating journey. Traditionally, antidepressants like SSRIs (Selective Serotonin Reuptake Inhibitors) have been the go-to option. However, Ketamine Therapy is emerging as a powerful alternative, offering rapid relief for patients who haven't responded to conventional treatment. So, which option is better for long-term mental health recovery: antidepressants or Ketamine Therapy?
If you're considering Ketamine Therapy in Boulder or evaluating your current treatment plan, this guide will help you understand the key differences, effectiveness, risks, and benefits of both.
Antidepressants are medications designed to balance brain chemicals like serotonin, dopamine, and norepinephrine. Common types include: SSRIs (e.g., Prozac, Zoloft)
(e.g., Prozac, Zoloft) SNRIs (e.g., Effexor, Cymbalta)
(e.g., Effexor, Cymbalta) Tricyclics and MAOIs (less commonly prescribed due to side effects)
These medications generally take 2–6 weeks to show results and are often used alongside therapy.
Ketamine Therapy, particularly in the form of IV infusions or intranasal esketamine (Spravato), targets the glutamate system, promoting neural plasticity and rapid mood improvement.
Clinics offering Ketamine Therapy in Boulder report that many patients feel better within hours to days of their first treatment. It's often used for treatment-resistant depression (TRD) and suicidal ideation.
Antidepressants increase the availability of serotonin and other neurotransmitters. They aim to regulate mood over time but do not typically address the brain's structural changes linked to long-term depression.
Limitations: Slower onset
Common side effects (e.g., weight gain, ****** dysfunction, fatigue)
Emotional blunting
Ketamine works by blocking NMDA receptors, enhancing glutamate activity and promoting synaptogenesis—the creation of new neural connections.
Advantages: Fast-acting (within hours)
May reverse structural brain damage caused by chronic stress
Strong effects on suicidal ideation
Recent studies have shown that Ketamine Therapy in Boulder and similar clinics across the U.S. report high success rates, especially for patients who haven't responded to 2+ antidepressants. According to a 2018 meta-analysis in The Lancet , 60% of people experience some improvement with antidepressants, but relapse is common.
, 60% of people experience some improvement with antidepressants, but relapse is common. 33% of patients relapse within a year of stopping medication.
Many require long-term use, leading to increased risk of side effects and dependency. A 2020 study published in JAMA Psychiatry found that 70% of patients with TRD responded positively to ketamine.
found that 70% of patients with TRD responded positively to ketamine. Another study in The American Journal of Psychiatry reported reduced suicidal ideation within 24 hours of treatment.
reported reduced suicidal ideation within 24 hours of treatment. Long-term effectiveness depends on maintenance treatments and integration with therapy.
Clinics offering Ketamine Therapy in Boulder often combine infusions with psychotherapy to sustain results, significantly reducing relapse rates. Common: Insomnia, fatigue, nausea, ****** side effects
Severe (less common): Increased anxiety or suicidal thoughts during initial weeks
Long-term: Tolerance, emotional numbness, and withdrawal symptoms Common (short-term): Dissociation, dizziness, nausea, increased blood pressure
Rare (long-term): Bladder issues, dependency (in recreational use, not clinical)
Safe when administered in a medical setting like a certified Ketamine Therapy clinic in Boulder Generally covered by insurance
Low out-of-pocket costs
Widely available through primary care or psychiatry Can be more expensive per session (average $400–$800)
Spravato (nasal form) often covered by insurance
IV infusions may not be fully covered
However, many clinics offering Ketamine Therapy in Boulder provide flexible payment plans or work with insurance for partial reimbursement. Require daily medication
Often a trial-and-error process
Side effects can interfere with daily life Less frequent sessions (typically 6–8 over 2–3 weeks)
Immediate symptom relief can improve quality of life quickly
Enhanced engagement in therapy due to faster symptom reduction
Patients receiving Ketamine Therapy in Boulder frequently report improved motivation, better sleep, and enhanced social interactions after just a few sessions. You're experiencing mild to moderate depression
You have not tried any treatment yet
You prefer a cost-effective and accessible option You have treatment-resistant depression
You need rapid relief from suicidal ideation
You're looking for a non-traditional, science-backed alternative
Pro Tip: Many mental health professionals now recommend combining both for enhanced, long-term results. For example, ongoing antidepressants with booster ketamine sessions at a Ketamine Therapy clinic in Boulder can provide balanced, sustainable mental health support.
Claire, a 36-year-old Boulder resident, struggled with major depression for over a decade. After trying five different antidepressants with minimal success, she discovered Ketamine Therapy in Boulder.
'I felt better within 24 hours of my first session,' Claire shares. 'It gave me the clarity and energy to engage in therapy again. I wish I had tried this sooner.'
Her current regimen includes monthly maintenance ketamine infusions and weekly CBT sessions. She reports an 80% reduction in depressive symptoms and is back to working full-time.
Both antidepressants and Ketamine Therapy can be effective—depending on the individual. However, for patients with TRD, ketamine offers significant advantages in speed, depth of relief, and neurobiological repair.
That said, Ketamine Therapy isn't a standalone cure. It works best when paired with therapy and lifestyle adjustments. Clinics providing Ketamine Therapy in Boulder understand this and often offer integrative care models to support long-term success.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
4 hours ago
- San Francisco Chronicle
More dental problems as you get older? Aging may not be the real reason
Older people are living longer and keeping more of their teeth. That's good news — but it also means that seniors need to be more vigilant than ever about oral health. Over the past 20 years, the portion of adults 65 and older with no teeth fell from about 32% to an all-time low of 17%, according to the most recent report from the National Institute of Dental and Craniofacial Research. Among those 75 and older, it fell from 38% to 22%. 'More people are keeping more of their teeth for longer,' said Dr. Don Curtis, a professor at UCSF School of Dentistry. 'So there's more teeth to take care of and more teeth that are vulnerable to chronic disease.' Older adults are at higher risk than younger populations for developing many dental problems, including periodontal disease (gum disease), root cavities and oral cancer. About 66% of U.S. adults 75 and older have periodontitis (serious gum disease) compared to 42% in the overall adult population, according to one 2016 estimate. Aging may not be the reason These dental issues aren't necessarily due to aging itself, but rather other things that often happen with your overall health, mobility, dexterity and cognition as you age that can in turn affect your oral health, dentists say. For example, many older adults take multiple prescription medications to manage chronic diseases like diabetes, heart disease and osteoporosis. One of the most common side effects of using multiple medications is dry mouth, or having less saliva (hyposalivation), which can make you more susceptible to cavities — one major contributor to losing teeth. Even some common medications for allergies can disrupt saliva flow, as can SSRIs, a class of antidepressants whose side effects can include grinding and clenching. Grinding over time can wear down tooth enamel and make a person more vulnerable to tooth loss. 'Hundreds of medications can cause disturbed salivary flow,' said Dr. Elisa Chavez, a professor at the University of Pacific School of Dentistry in San Francisco. 'Often, people aren't thinking about it or it doesn't strike them as critical. But these are things that can increase risk of developing cavities.' More than 30% of patients over age 60 suffer from dry mouth, according to one 2014 study in the Journal of Dentistry. Gum recession also tends to become more common with age. Recession exposes more of the roots of the teeth where plaque accumulates, which can cause decay and heighten the risk of gum disease. 'The average 70-year-old is more vulnerable to decay because of gum recession than a 7-year-old,' Curtis said. 'Everyone thinks once they're an adult they're not going to get cavities anymore but that's not the case.' Studies have also found that people with diabetes, a chronic condition that's more common in older adults, are at higher risk for gum disease and loose teeth. Some older adults also have problems with mobility because of arthritis or tremors, which can make it harder to brush and floss regularly or get to the dentist as often as they used to. Cognitive impairment can also complicate matters, making it harder to remember daily oral hygiene or to point out a new problem, like bleeding gums. One 2013 study found that among homebound elderly adults, 96% said they had not seen a dentist since becoming homebound. 'For patients who have significant cognitive issues, having regular dental visits are important because they may not be able to identify things like a well older adult would,' Chavez said. 'Those opportunities for intervention early on are really important in that population.' But, perhaps hearteningly, 'Poor oral health is not an inevitability of aging,' Chavez said. 'You can maintain good oral health,' she said. 'The thing is to identify risk factors — the presence of chronic diseases that result in loss of ability to care for yourself or get regular care, and medications that can have an impact.' Interdental brushes, and other solutions Let your dentist know if you've been diagnosed with a new condition or started any new medications since you last saw them, Chavez said. This includes flagging any changes in your ability to maintain daily oral hygiene. 'Dentists and hygienists can give you points and ideas about oral hygiene aids,' she said. For older adults with limited dexterity, for instance, at-home tools like interdental brushes, oral rinses, irrigation devices and power toothbrushes can be helpful, according to a 2021 study led by UCSF's Curtis that examined how to treat older adults with periodontal disease. Curtis recommends using an electric toothbrush with a timer. 'Without a timer, many people often think they spent adequate time but they haven't so they're leaving plaque, which is what leads to potential decay and inflammation associated with periodontal disease,' he said. After eating, brush first, then floss, then brush a little more, Curtis said. This is because flossing helps break up plaque colonies between the teeth. If you grind your teeth, consider a night guard, which can help lessen damage and tooth loss. Older adults with gum recession can also ask their dentist about a high-fluoride varnish. In 2022, a Department of Veterans Affairs study of about 68,000 older adults found that the topic varnish applied over the roots helped decrease decay by 29% over a three-year period. 'Dentures are not a foregone conclusion,' Chavez said. 'We can maintain oral health into older ages and that's exactly what we want to do.'
Yahoo
6 hours ago
- Yahoo
Scientists track 25 years of submicron air pollution particles across US skies
Air pollution is a serious and often underestimated health threat in the U.S. It is linked to over 50,000 premature deaths each year. Tiny particles in the air, like PM2.5, can get embedded into a person's lungs and bloodstream, leading to chronic heart and lung problems. PM2.5 refers to particulate matter that is smaller than 2.5 micron. While scientists have studied these particles for decades, far less is known about PM1— even smaller at under 1 micron—whose effect on human health could be equally lethal, if not more. A new study from Washington University in St. Louis, published in The Lancet Planetary Health, has mapped 25 years of PM1 air pollution across the United States. The findings offer a starting point for identifying which pollutants regulators should target to improve public health. The research also builds on the university's expertise in satellite sensing and atmospheric modeling. According to Chi Li, research assistant professor at the university's Atmospheric Composition Analysis Group and lead author of the study, the new estimates will help researchers better understand the impact of submicron particles. These tiny particles often come from direct emissions, like black carbon from diesel engines or smoke from wildfires. They can also form indirectly when pollutants such as sulfur dioxide or nitrogen oxides are released from fuel combustion and coal burning. Rather than being made of a single substance, air particles are usually mixtures of various materials layered together. Li noted that larger particles are often dominated by components like mineral dust, which are more difficult to regulate or reduce. The researchers estimated PM1 levels by analyzing the known composition of PM2.5 particles, which include seven main components such as sulfate, nitrate, and mineral dust. By combining these elements, the team was able to calculate PM1 concentrations across the US. The study lays the groundwork for deeper analysis of where these tiny particles tend to concentrate, how they form, and what impacts they have on both human health and the environment. PM1 pollution particles may be more harmful because they can penetrate deeper into the body, slipping past natural defenses. These submicron particles are at least six times smaller than a blood cell. According to Jay Turner, the James McKelvey Professor of Engineering Education and co-author of the study, when the United States Environmental Protection Agency (EPA) first set air quality standards for fine particulate matter in 1997, there was significant debate over whether to regulate PM1 or PM2.5. Due to limited health impact research on PM1 compared to PM2.5, the EPA chose to focus on PM2.5. However, the new dataset revealed encouraging insights: pollution regulation has significantly reduced PM1 levels across the contiguous U.S. from 1998 to 2022, largely due to environmental policies like the Clean Air Act. But this progress has slowed since 2010, mainly because of increasing wildfire activity. Although countries like China have gotten a head start in tracking PM1, U.S. can catch up with the help of this comprehensive nationwide dataset. The next step will entail collaboration with epidemiologists to assess how exposure to these tiny particles relates to various health outcomes.
Yahoo
a day ago
- Yahoo
The cost of staying alive could become a lot more expensive for millions of Americans because of Trump drug tariffs
Americans would likely pay more for necessary everyday prescription drugs, such as insulin, painkillers, chemotherapy, or antibiotics, if President Donald Trump were to enact tariffs on pharmaceuticals, experts warn. In an effort to incentivize drug manufacturers to bring production back to the United States, Trump has proposed tariffing pharmaceuticals made overseas – which account for an overwhelming majority of everyday medicine used in the U.S. 'We're going to be doing that,' Trump said of pharmaceutical tariffs in April. 'That's going to be like we have on cars. You know we have a 25 percent tariff on cars, we have a 25 percent tariff on steel and aluminum, and that's what the [pharmaceutical] category fits right now.' 'The higher the tariff, the faster they come,' Trump said. But experts say that's not necessarily true and there would be tangible consequences to such action, from higher brand-name drug prices to generic drug shortages. 'If tariffs were applied to prescription drugs, one of the most immediate consequences could be price increases — on prices that we already pay way in excess of other countries,' Dr. Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, said. The U.S. imports a majority of its branded prescription drugs – or medications that are patented with a brand name such as Viagra, Wegovy, or Zoloft – from high-income countries. Dr. Jeromie Ballreich, an associated research professor at Johns Hopkins Bloomberg School of Public Health, said much of the manufacturing comes from Ireland, Germany, and Switzerland because they have favorable tax policies for companies. As a result, adding a tariff would only make it more expensive for pharmacies and insurance companies to keep them in supply. 'We would expect pharma to pass the costs onto the insurers and we would expect insurers to pass the cost onto the individual patients,' Ballreich said. 'So, if there is a 50 percent tariff on your insulin product because it's coming from Ireland, patients in Mississippi who get insulin – they will either be faced with a higher cost when they go up to the pharmacy to fill their insulin or they're going to face a higher indirect cost because the premiums of the insurance plan are going to go up,' he said. Ballreich said a tariff on countries that produce high quantities of branded drugs would put 'pressure' on public insurers like Medicare or Medicaid and private insurers. However, branded drugs only account for roughly 10 to 15 percent of prescriptions. A majority of Americans, up to 90 percent, use generic drugs, often manufactured in India and China, because they're cheaper. Making branded drugs less accessible through tariffs would only increase reliance on generic drugs, which could exacerbate shortages that already impact millions of Americans. '[Shortages] can have very significant implications in day-to-day clinical practice,' Socal said. 'For example, if you are administering chemotherapy for an oncology patient, that may have significant consequences even for the prognosis of that case moving forward.' In 2024, the U.S. experienced a shortage of more than 300 drugs – 70 percent of which were generic prescriptions. Socal said that when patients are not able to access a more affordable version of their prescription, it means they may put their health at risk by skipping a dosage, taking a lower dosage, or not filling their prescription at all. Otherwise, they're forced to turn to the more expensive branded version. 'Those more expensive drugs are not always the best,' Socal said. 'Very frequently, and we saw this with chemotherapy shortages, the available drugs are second-line drugs.' The president has indicated that any negative impact from tariffs may be temporary and worth it to bring manufacturing and jobs back. 'We're doing it because we want to make our own drugs,' Trump said. But Ballreich and Socal are more skeptical. 'Tariffs are a very blunt instrument to incentivize domestic U.S. manufacturing of the branded drugs we use,' Ballreich said. Given pharmaceutical companies have moved outside of the U.S. for tax purposes, Ballreich says tax policy may be a better way to incentivize them, especially since many of those drugs are more difficult to manufacture. 'It's not just a very simple chemical plant; these tend to be very complex,' he said. Socal suggested a better strategy would be to understand where drugs are being manufactured and which ones would make more sense to bring to the U.S. — since even those manufactured locally often rely on certain imported ingredients and materials. 'Having tariffs on pharmaceutical products coming from abroad can actually also hurt our domestic manufacturers,' he says. While the president has not officially implemented any tariff policy on pharmaceuticals yet, he said, in April, that the plan would take effect in the 'not too distant future.'
